CBD must be Rescheduled by the DEAJuly 13, 2018
CBD must be Rescheduled by the DEA to uphold the Controlled Substance Act.
CBD’s current listing as a Schedule I drug suggests that it has “no known medicinal value” with a high potential for abuse. To give you some perspective, other Schedule I drugs include heroin, LSD, mescaline and methylenedioxymethamphetamine (better known as “ecstasy”).
The FDA cannot allow Epidiolex to go to market without making a change. It is the same reason that opioid medications, like OxyContin and Percocet, are listed as Schedule II even though these narcotics are essentially the same drug as heroin – listed Schedule I. Because they want to use them as medicine for profits. Earlier this year Massachusetts Sued Oxycontin Maker Purdue Pharma Saying It Peddled Falsehoods.
The U.S. Food and Drug Administration (FDA) admitted that parts of the cannabis plant, something that the U.S. government has considered a gateway to addiction for the past several decades, has a place in the treatment of patients suffering from severe forms of epilepsy.
It was just a few weeks ago that the FDA gave GW Pharmaceuticals permission to start slinging Epidiolex to epilepsy patients here in the states. The solution, which has been shown effective in reducing seizures in children with Lennox-Gastaut syndrome and Dravet syndrome, will soon be available with a prescription through all major pharmacy chains. Typically, the syndromes begin at a very young age, which is why the FDA approved use of the drug for those ages two or older. Epidiolex is the only drug approved for treatment of Dravet syndrome, according to the Washington Post.
Barbara Carreno, a public affairs representative for the DEA, says the agency has 90 days to put CBD into a lower classification. The change is already in progress. The DEA’s pending action with respect to CBD is a prerequisite to the launch of Epidiolex.